Plain-English translation of NCT07252323 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing carbon ion radiotherapy, a specialized type of radiation treatment that uses carbon particles instead of standard X-rays to target liver cancer more precisely. You may qualify if your liver cancer has come back or didn't fully respond to a previous treatment called transarterial radioembolization (TARE). The goal is to see whether this advanced radiation can control the cancer while protecting your healthy liver tissue.
Many patients with liver cancer don't respond fully to their first treatment, and they have limited options for what to try next. This trial exists to find out whether carbon ion radiotherapy—which delivers radiation more precisely and with greater killing power than standard radiation—could be an effective next step for these patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll receive carbon ion radiotherapy delivered over several visits using a customized plan based on your tumor's size and location. Your doctor will design the treatment to maximize the dose to your cancer while minimizing exposure to healthy liver tissue. You'll have scheduled follow-up appointments with imaging scans, blood tests, and check-ins to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
South Korea